🇺🇸 FDA
Patent

US 12053526

Methods for treatment using anti-alpha4beta7 antibody

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 12053526 (Methods for treatment using anti-alpha4beta7 antibody) held by Takeda Pharmaceutical Company Limited expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/395